Ligand Evolution in the Photoactivatable Platinum(IV) Anticancer Prodrugs
Photoactivatable Pt(IV) anticancer prodrugs with the structure of [PtIV(N1)(N2)(L1)(L2)(A1)(A2)], where N1 and N2 are non-leaving nitrogen donor ligands, L1 and L2 are leaving ligands, and A1 and A2 are axial ligands, have attracted increasing attention due to their promising photo-cytotoxicity even to cisplatin-resistant cancer cells. These photochemotherapeutic prodrugs have high dark-stability under physiological conditions, while they can be activated by visible light restrained at the disease areas, as a consequence showing higher spatial and temporal controllability and much more safety than conventional chemotherapy. The coordinated ligands to the Pt center have been proved to be pivotal in determining the function and activity of the photoactivatable Pt(IV) prodrugs. In this review, we will focus on the development of the coordinated ligands in such Pt(IV) prodrugs and discuss the effects of diverse ligands on their photochemistry and photoactivity as well as the future evolution directions of the ligands. We hope this review can help to facilitate the design and development of novel photoactivatable Pt(IV) anticancer prodrugs.
Top-30
Journals
|
1
2
3
|
|
|
International Journal of Molecular Sciences
3 publications, 13.64%
|
|
|
Coordination Chemistry Reviews
3 publications, 13.64%
|
|
|
Drug Delivery
1 publication, 4.55%
|
|
|
Inorganics
1 publication, 4.55%
|
|
|
Current Opinion in Chemical Biology
1 publication, 4.55%
|
|
|
Frontiers in Pharmacology
1 publication, 4.55%
|
|
|
Molecules
1 publication, 4.55%
|
|
|
Chemical Communications
1 publication, 4.55%
|
|
|
Dalton Transactions
1 publication, 4.55%
|
|
|
ACS Applied Nano Materials
1 publication, 4.55%
|
|
|
Angewandte Chemie
1 publication, 4.55%
|
|
|
Angewandte Chemie - International Edition
1 publication, 4.55%
|
|
|
ChemMedChem
1 publication, 4.55%
|
|
|
Mendeleev Communications
1 publication, 4.55%
|
|
|
Pharmaceuticals
1 publication, 4.55%
|
|
|
Chemical Reviews
1 publication, 4.55%
|
|
|
Nature Communications
1 publication, 4.55%
|
|
|
Chemical Biology and Drug Design
1 publication, 4.55%
|
|
|
1
2
3
|
Publishers
|
1
2
3
4
5
6
|
|
|
MDPI
6 publications, 27.27%
|
|
|
Elsevier
4 publications, 18.18%
|
|
|
Wiley
4 publications, 18.18%
|
|
|
Royal Society of Chemistry (RSC)
2 publications, 9.09%
|
|
|
American Chemical Society (ACS)
2 publications, 9.09%
|
|
|
Taylor & Francis
1 publication, 4.55%
|
|
|
Frontiers Media S.A.
1 publication, 4.55%
|
|
|
OOO Zhurnal "Mendeleevskie Soobshcheniya"
1 publication, 4.55%
|
|
|
Springer Nature
1 publication, 4.55%
|
|
|
1
2
3
4
5
6
|
- We do not take into account publications without a DOI.
- Statistics recalculated weekly.